No differences were observed in systolic blood pressure (SBP) or medical therapy for HF, except that patients with lower obesity class were more likely to be treated with sodium-glucose co-transporter-2 (SGLT2) inhibitors, and patients with higher obesity class were more likely to receive loop diuretics at higher dose. The gene discussed is SLC5A2; the disease is hydrops fetalis.